National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy

被引:8
|
作者
Prunty, Megan [1 ,2 ]
Rhodes, Stephen [2 ]
Rivero, Marco-Jose [1 ]
Callegari, Michael [1 ,2 ]
Jesse, Erin [1 ,2 ]
Arenas-Gallo, Camilo [1 ,2 ]
Brant, Aaron [3 ]
Calaway, Adam [1 ,2 ]
Scherr, Douglas
Shoag, Jonathan E. [1 ,2 ,3 ]
机构
[1] Case Western Reserve Univ, Dept Urol, Sch Med, Cleveland, OH USA
[2] Univ Hosp Cleveland, Inst Urol, Med Ctr, Cleveland, OH USA
[3] Weill Cornell Med, New York Presbyterian Hosp, Dept Urol, New York, NY USA
关键词
cystectomy; urinary bladder neoplasms; antibiotic prophylaxis; infections; RISK-FACTORS; BLADDER; STATEMENT;
D O I
10.1097/JU.0000000000003069
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The sentinel reference for antibiotic prophylaxis for radical cystectomy with ileal conduit in the AUA Guidelines reports data from 2003-2013 and has not been updated in the interim. Here, we assess adherence to antibiotic prophylaxis guidelines among patients undergoing radical cystectomy with ileal conduit for bladder cancer using a large national database. As a secondary objective, we assess the association between antimicrobial use and postoperative infection during the index admission following cystectomy. Materials and Methods: The Premier Healthcare Database was queried for all patients undergoing cystectomy with ileal conduit with diagnosis of bladder cancer between 2015 and 2020. Antibiotics used and the duration of use was determined by charge codes and grouped as guidelines-based or not according to 2019 AUA Guidelines. Association with infectious complications was assessed by logistic mixed effects regression models. Results: Among 6,708 patients undergoing cystectomy with ileal conduit, only 28% (1,843/6,708) were given prophylaxis according to AUA guidelines; 1.8% (121/6,708) of patients received an antifungal and 37% (2,482/6,708) received extended duration prophylaxis beyond postoperative day 1. Patients who received guidelines-based prophylaxis were less likely to be diagnosed with a urinary tract infection (21% vs 24%, P [.04), pyelonephritis (5.1% vs 7.7%, P <.001), bacterial infection (24% vs 27%, P [.03), or pneumonia (12% vs 17%, P <.001). There was no statistically significant difference in clostridium difficile infection between guidelines-based and nonguidelines-based prophylaxis (3.2% vs 3.7%, P [.32). In a multivariable logistic regression adjusting for age, race, insurance, and hospital and provider characteristics, nonguideline antibiotic prophylaxis (OR 1.27 [1.12, 1.43], P <.001) was associated with an increased odds of infectious events, whereas a robotic approach (OR 0.82 [0.73, 0.92], P <.001) was associated with lower odds. Conclusions: Seventy-three percent of patients fail to receive guideline-based antibiotic prophylaxis when undergoing radical cystectomy with conduit, which was largely driven by extended duration antibiotic use. Despite the shorter duration of antibiotics, we found that guideline-based prophylaxis was associated with a 25% decrease in the odds of infectious complications. While residual confounding is possible, these data support current AUA guidelines and suggest a need for outreach to improve guideline adherence.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 50 条
  • [21] Impact of marital status in patients undergoing radical cystectomy for bladder cancer
    Pruthi, Raj S.
    Lentz, Aaron C.
    Sand, Matthew
    Kouba, Erik
    Wallen, Eric M.
    WORLD JOURNAL OF UROLOGY, 2009, 27 (04) : 573 - 576
  • [22] Impact of marital status in patients undergoing radical cystectomy for bladder cancer
    Raj S. Pruthi
    Aaron C. Lentz
    Matthew Sand
    Erik Kouba
    Eric M. Wallen
    World Journal of Urology, 2009, 27 : 573 - 576
  • [23] The importance of lymphovascular invasion in patients undergoing radical cystectomy for bladder cancer
    Stein, JP
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (05): : 246 - 247
  • [24] Factors influencing the choice of urinary diversion in patients undergoing radical cystectomy
    Ashley, Matt S.
    Daneshmand, Siamak
    BJU INTERNATIONAL, 2010, 106 (05) : 654 - 657
  • [25] The impact of preoperative anemia on oncologic outcome in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
    Jung Ki Jo
    Seong Jin Jeong
    Sung Kyu Hong
    Seok-Soo Byun
    Sang Eun Lee
    Jong Jin Oh
    International Urology and Nephrology, 2016, 48 : 489 - 494
  • [26] The Feasibility of a Health Care Application in the Treatment of Patients Undergoing Radical Cystectomy
    Metcalf, Meredith
    Glazyrine, Vassili
    Glavin, Katie
    Dahlgren, Alexandra
    Michael, Carrie
    Bechtel, Misty
    Bishop, David
    DeRuyter, Martin
    Mirza, Moben
    Taylor, John
    Wyre, Hadley W.
    Hamilton-Reeves, Jill M.
    Holzbeierlein, Jeffrey M.
    Lee, Eugene K.
    JOURNAL OF UROLOGY, 2019, 201 (05) : 902 - 908
  • [27] Implementation of the Exeter Enhanced Recovery Programme for patients undergoing radical cystectomy
    Dutton, Thomas J.
    Daugherty, Mark O.
    Mason, Robert G.
    McGrath, John S.
    BJU INTERNATIONAL, 2014, 113 (05) : 719 - 725
  • [28] Incidence and Risk Factors of Parastomal Hernia in Patients Undergoing Radical Cystectomy and Ileal Conduit Diversion
    Liu, Nick W.
    Hackney, Jeromy T.
    Gellhaus, Paul T.
    Monn, M. Francesca
    Masterson, Timothy A.
    Bihrle, Richard
    Gardner, Thomas A.
    House, Michael G.
    Koch, Michael O.
    JOURNAL OF UROLOGY, 2014, 191 (05) : 1313 - 1318
  • [29] Characteristics and Associated Factors of Postoperative Pulmonary Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer: A National Surgical Quality Improvement Program Study
    Xia, Leilei
    Taylor, Benjamin L.
    Guzzo, Thomas J.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : 661 - 669
  • [30] Sarcopenia as an independent predictor for venous thromboembolism events in bladder cancer patients undergoing radical cystectomy
    Gao, Jie
    Shi, Yingxin
    Zhou, Diansheng
    Zhang, Yu
    Tian, Dawei
    Wu, Changli
    SUPPORTIVE CARE IN CANCER, 2022, 30 (02) : 1191 - 1198